Appendix 3X (Initial Director’s Interest Notice) in relation to the appointment of Dr. Hazle effective July 30th, 2018.
View and download Appointment of Director and Appendix 3X.
Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent
January 31, 2026
Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has